Wealth Enhancement Advisory Services’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
Wealth Enhancement Advisory Services's CRL Position: Q3 2026 in Review
Wealth Enhancement Advisory Services increased its Charles River Laboratories (CRL) stake by 8% in Q3 2026, buying an estimated $82.2K and bringing the position to 4,208 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2018.
Wealth Enhancement Advisory Services first reported a position in CRL in Q3 2021 and has held it in 14 quarters since. The position peaked at $8.3M in Q3 2021. 635 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- Wealth Enhancement Advisory Services held 4,208 shares of Charles River Laboratories worth $1.25M as of Q3 2026.
- Wealth Enhancement Advisory Services bought 312 Charles River Laboratories shares in Q3 2026, an estimated $82.2K.
- Charles River Laboratories made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #2018 holding.
- Wealth Enhancement Advisory Services first reported a position in Charles River Laboratories in Q3 2021 and has held it in 14 quarters since.
- Wealth Enhancement Advisory Services's Charles River Laboratories position peaked at $8.3M in Q3 2021.
- 635 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.